Nos publications

Unveiling the Potential of Labrasol® ALF Labrafac™ MC60 and Capryol® 90 as Permeation Enhancers to Address Low Bioavailability Issues

  • Whitepaper

American Pharmaceutical Review - oct 2024

Cécile Morin, Philippe Caisse

In vitro, ex vivo, and in vivo tests show that Labrasol® ALF, Labrafac™ MC60, and Capryol® 90 are effective and safe permeation enhancers. They work by temporarily opening tight junctions in the intestinal lining, potentially improving the bioavailability of poorly permeable drugs, including small molecules (BCS III and IV) and large molecules like peptides and proteins.

Labrafac™ MC60 is an efficacious intestinal permeation enhancer for macromolecules: Comparisons with Labrasol® ALF in ex vivo and in vivo rat studies

  • Scientific publication

International Journal of Pharmaceutics - jui 2024

Fiona McCartney, Philippe Caisse, Camille Dumont, David Brayden

In this article, demonstration on how Labrafac™ MC60 acts as a safe intestinal permeation enhancer is given, with insulin as a model molecule. Studies were conducted in vivo and ex vivo, using isolated muscle-stripped rat jejunal and colonic mucosae.

In vivo confirmation of the permeation enhancement capacity of Labrafac™ MC60

  • Poster

AAPS PharmSci360 – Orlando (USA) - oct 2023

Fiona McCartney, Philippe Caisse , Camille Dumont, David J. Brayden

Labrafac™ MC60 acts as an intestinal permeation enhancer in isolated rat colonic and jejunal mucosae in the Ussing chambers

  • Poster

CRS Annual Meeting – Montreal (Canada)  - jui 2022

Fiona McCartney ; Camille Dumont ; Philippe Caisse and David J. Brayden